( - XIENCE V Demonstrates Superiority in ...)Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial,Health

ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial at the of Cardiology's 56th Annual Scientific Session in New Orleans demonstrated the following key results:

    --  The randomized SPIRIT III trial of 1,002 patients comparing Abbott's

        next-generation XIENCE(TM) V Everolimus Eluting Coronary Stent System

        with the TAXUS(R) paclitaxel-eluting coronary stent system met both

        its primary endpoint and major secondary endpoint.

    --  In its primary endpoint of in-segment late loss at eight months,

        XIENCE V demonstrated superiority to TAXUS with a statistically

        significant 50 percent reduction in late loss compared to TAXUS (0.14

        +/- 0.41 mm XIENCE V, 0.28 +/- 0.48 mm TAXUS, p superior =0.004).

        In-segment late loss is a measure of vessel renarrowing.

    --  In its major secondary endpoint of Target Vessel Failure at nine

        months, XIENCE V demonstrated non-inferiority to TAXUS with an

        observed 21 percent reduction in Target Vessel Failure for XIENCE V

        compared to TAXUS (7.2 percent XIENCE V, 9.0 percent TAXUS, p non-

        inferior <0.0001).  Target Vessel Failure is a measure of re-treatment

        anywhere within the target vessel and includes cardiac death or heart

        attack.

    --  Subsequent to SPIRIT III meeting its primary and major secondary

        endpoints, an analysis of nine-month Major Adverse Cardiac Events

        (MACE), such as cardiac death, heart attack or target lesion

        revascularization (artery re-treatment due to lack of blood supply),

        was undertaken in which XIENCE V demonstrated superiority to TAXUS

'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
2. New Analysis of Data Shows Treatment With Abbotts Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohns Disease
3. Abbotts Investigational Treatment ABT-874 Shows Positive Results
in Phase II Psoriasis Study
4. Abbott Announces Continued Positive Results with Xience V
Everolimus Eluting Coronary Stent in Spirit Clinical Trials
5. New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings
6. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares
Favorably to Drug-Eluting Stents
7. Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial
Results at EuroPCR 2007
9. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus
Drug-Eluting Coronary Stent Systems
10. Medtronic Announces Positive Nine-Month Results for Endeavor
Resolute Next Generation Drug-Eluting Stent at EuroPCR
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes
for Moderate-Release Paclitaxel-Eluting Stent at Four Years